<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00209222</url>
  </required_header>
  <id_info>
    <org_study_id>MCL2004-2</org_study_id>
    <nct_id>NCT00209222</nct_id>
  </id_info>
  <brief_title>Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL</brief_title>
  <official_title>Efficacy of 6x R-CHOP Followed by Myeloablative Radiochemotherapy and Autologous Stem Cell Transplantation vs. 3 x (R-CHOP/R-DHAP) Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Mantle Cell Lymphoma Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Low Grade Lymphoma Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lymphoma Study Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Mantle Cell Lymphoma Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether alternating courses of cyclophosphamide,
      doxorubicin, vincristine, prednisone/dexamethasone, cytarabine, cisplatin (CHOP/DHAP) plus
      rituximab followed by total body irradiation [TBI]/high dose cytarabine
      [ARA-C]/melphalan-peripheral blood stem cell transplantation (TAM-PBSCT) can improve the time
      to treatment failure compared to CHOP plus rituximab followed by standard PBSCT
      (dexamethasone, carmustine, cytarabine, etoposide, and melphalan [Dexa-BEAM]/TBI/high dose
      cyclophosphamide) in patients with untreated mantle cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently, a prospective randomized intergroup trial of the European MCL Network has shown
      that a myeloablative radio-chemotherapy followed by autologous stem cell transplantation
      (PBSCT) improves event-free survival (EFS) when compared to a interferon alpha maintenance
      therapy after a CHOP-like induction. However, the CR rate after the CHOP induction was still
      low (&lt;20%). Thus, several studies have been conducted to increase the CR rate of induction
      therapy to further improve event-free and overall survival. Two recent phase II trials
      suggest that induction regimens containing high dose Ara-C may significantly improve the CR
      rate up to 80%. In addition, a number of studies provide evidence that the humanized
      anti-CD20 antibody Rituximab may induce significant responses in relapsed MCL. A prospective
      randomized study of the GLSG demonstrated that a combined immuno-chemotherapy (CHOP plus
      Rituximab) induces a significantly higher response rate than CHOP alone.

      The aim of this study is the comparison of the current standard (R-CHOP followed by
      myeloablative radio-chemotherapy and subsequent blood stem cell transplantation) to a new
      alternating induction regimen containing high dose Ara-C (R-CHOP/DHAP) followed by a high
      dose ARA-C containing myeloablative radio-chemotherapy and PBSCT.

      This study will be performed as a prospective, randomized, open-label multicenter phase III
      trial. All patients will be initial randomized for standard treatment versus experimental
      treatment.

      REFERENCE ARM:

      The induction therapy consists of 6 cycles of a CHOP chemotherapy in combination with
      Rituximab. If the mantle cell lymphoma is progressive after 4 cycles of chemotherapy,
      patients will be taken off study. Patients achieving at least a partial remission after 6
      cycles R-CHOP will proceed to intensified consolidation (Dexa-BEAM) with stem cell collection
      and subsequent myelo-ablative radio-chemotherapy (TBI/High Dose Cyclophosphamide) with
      autologous stem cells transplantation

      EXPERIMENTAL ARM:

      Initial cytoreductive chemotherapy comprises of alternating cycles of 3xCHOP and 3x DHAP plus
      Rituximab. Patients with progressive disease after 2 treatment cycles R-CHOP and 2x R-DHAP
      will be off study. Patients achieving at least a partial remission after 3x CHOP and 3x DHAP
      plus Rituximab will proceed to with stem cell collection. The subsequent myeloablative
      radio-chemotherapy with stem cell transplantation consists of a radiotherapy (TBI), high dose
      Ara-C and Melphalan.

      The primary end point in this study is the time to treatment failure. The time to treatment
      failure will be defined as time from start of initial therapy until first failure. A failure
      will be defined as failure of initial therapy or progression of the lymphoma or death of the
      patient.

      Using the data of the PBSCT group in the former European mantle cell study as baseline in a
      proportional hazard model, the improvement for the time to treatment failure expected by the
      new strategy can be expressed by reduction of relative risk (rr). A risk reduction to 52%
      which would correspond to a improvement of 20% in failure free survival after 3 years seems
      to be a clinical relevant improvement. For a working significance level alpha=0.05 and a
      power of 95% the number of events necessary for a one sided fixed sample trial is about 105.
      During this study the time to treatment failure will be monitored using an equivalent
      one-sided triangular sequential test.

      In order to evaluate the impact of therapy on overall survival in this patients, a total
      follow up of about 12 years for this study is expected.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2004</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to treatment failure after start of therapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete remission (CR) rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serious infectious complications</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Lymphoma, Mantle-Cell</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>induction: R-CHOP consoldiation : TBI/Cyclo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>induction: R-CHOP/DHAP consolditaion: TBI/TAM</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>antibody</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>chemotherapy</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>chemotherapy</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>chemotherapy</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>corticosteroide</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatinum</intervention_name>
    <description>chemotherapy</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara-C</intervention_name>
    <description>chemotherapy</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>corticosteroide</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCNU</intervention_name>
    <description>chemotherapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>chemotherapy</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>chemotherapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>growth factor</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemotherapy: R-CHOP</intervention_name>
    <description>immuno-chemotherapy</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemotherapy: R-DHAP</intervention_name>
    <description>immuno-chemotherapy</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemotherapy: Dexa-BEAM</intervention_name>
    <description>chemotherapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>stem cell harvest</intervention_name>
    <description>procedure</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>total body irradiation</intervention_name>
    <description>radiation</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>high-dose chemotherapy: Cyclophosphamide</intervention_name>
    <description>chemotherapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>high-dose chemotherapy: Ara-C /Melphalan</intervention_name>
    <description>chemotherapy</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven diagnosis of mantle cell lymphoma (World Health Organization
             [WHO] classification)

          -  Clinical stage II - IV (Ann Arbor)

          -  Previously untreated patients

          -  Age 18 - 65 years

          -  WHO performance &lt; 2

          -  Measurable disease (also: patients with isolated bone marrow involvement)

          -  Informed consent according to International Conference on Harmonisation of Technical
             Requirements for Registration of Pharmaceuticals for Human Use/European Union Good
             Clinical Practice (ICH/EU GCP) and national/local regulations

        Exclusion Criteria:

          -  Age &gt; 65 years

          -  WHO performance status &gt; 2

          -  Known anti-murine antibody (HAMA) reactivity or known hypersensitivity to murine
             antibodies

          -  Previous lymphoma therapy with radiation, cytostatic drugs, anti-CD20 antibody or
             interferon

          -  Serious disease interfering with a regular therapy according to the study protocol:

               -  cardiac (e.g. manifest heart failure, coronary heart disease, uncontrolled
                  hypertension)

               -  pulmonary (e.g. chronic lung disease with hypoxemia)

               -  endocrine (e.g. severe, not sufficiently controlled diabetes mellitus)

               -  renal insufficiency (unless caused by the lymphoma): creatinine &gt; 2x normal value
                  and/or creatinine clearance &lt; 50 ml/min)

               -  impairment of liver function (unless caused by the lymphoma): transaminases &gt; 3x
                  normal or bilirubin &gt; 2,0 mg/dl

          -  Patients with unresolved hepatitis B or C infection or known HIV infection

          -  Prior organ, bone marrow or peripheral blood stem cell transplantation

          -  Concomitant or previous malignancies within the last 5 years other than basal cell
             skin cancer or in situ uterine cervix cancer.

          -  Pregnancy or lactation

          -  Any psychological, familiar, sociological, or geographical condition potentially
             hampering compliance with the study protocol and follow up schedule
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Hermine, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Necker, Dept. of Adult Hematology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Hiddemann, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Großhadern/LMU, Dept. of Medicine III</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Unterhalt, Dr.</last_name>
    <phone>+49-89-7095</phone>
    <phone_ext>4915</phone_ext>
    <email>Michael.Unterhalt@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Dreyling, PhD</last_name>
    <phone>+49-89-7095</phone>
    <phone_ext>2202</phone_ext>
    <email>Martin.Dreyling@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Groupe D´Etudes des Lymphomes De l´Adulte (GELA)</name>
      <address>
        <city>Paris</city>
        <zip>F-75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guylène Chartier</last_name>
      <phone>+33-1-42499811</phone>
      <email>Guylene.chartier@chu-stlouis.fr</email>
    </contact>
    <contact_backup>
      <last_name>Olivier Hermine, PhD</last_name>
      <phone>+33-1-44 49 52 83</phone>
      <email>hermine@necker.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Olivier Hermine, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>German Low Grade Study Group (Glsg)</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Unterhalt, Dr.</last_name>
      <phone>+49-89-7095</phone>
      <phone_ext>4915</phone_ext>
      <email>Michael.Unterhalt@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Martin Dreyling, PhD</last_name>
      <phone>+49-89-7095</phone>
      <phone_ext>2202</phone_ext>
      <email>Martin.Dreyling@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Wolfgang Hiddemann, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Maria Sklodowska Memorial, Cancer Center - Inst. of Oncology</name>
      <address>
        <city>Warszawa</city>
        <zip>PL-02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Walewski, MD</last_name>
      <phone>+48-22-546-2223</phone>
      <email>walewski@coi.waw.pl</email>
    </contact>
    <contact_backup>
      <last_name>Marek P Nowacki, MD</last_name>
      <phone>+48-22-546-2223</phone>
    </contact_backup>
    <investigator>
      <last_name>Jan Walewski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005 Apr 1;105(7):2677-84. Epub 2004 Dec 9.</citation>
    <PMID>15591112</PMID>
  </reference>
  <reference>
    <citation>Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005 Mar 20;23(9):1984-92. Epub 2005 Jan 24.</citation>
    <PMID>15668467</PMID>
  </reference>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>September 7, 2012</last_update_submitted>
  <last_update_submitted_qc>September 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <name_title>Prof Dr. Martin Dreyling</name_title>
    <organization>University Hospital Grosshadern/European MCLNetwork</organization>
  </responsible_party>
  <keyword>Lymphoma, Mantle-Cell</keyword>
  <keyword>younger patients</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>high dose therapy</keyword>
  <keyword>C04.557.386.480.300.725.500</keyword>
  <keyword>C15.604.515.569.480.300.725.500</keyword>
  <keyword>C20.683.515.761.480.300.725.500</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

